Columbia University

Technology Ventures

Latest News

A new study by the Milken Institute ranks Columbia University as number two in the country for commercializing science and technology emerging from university research labs.

TheraPten Biosciences Inc., a Canadian biotechnology company, has entered into an exclusive licensing agreement with Columbia University on two globally issued patent families covering PTEN-L, a naturally-occurring tumor suppressor protein.

Applied Therapeutics Inc., today announced the closing of its Series A financing round. The financing was led by Alexandria Venture Investments alongside E Squared Capital Management, Franklin Berger, ETP Global Fund and Syno Capital. Joel S.

Doctor Rebecca Brachman has been selected as a TED Fellow, joining a class of 15 change-makers from around the world who will deliver a talk on the TED stage this April in Vancouver.

Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a promising first-in-class medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration (AMD).  

Fortress Biotech, Inc. announced the formation of a new subsidiary company, Caelum Biosciences, Inc., to advance the development of CAEL‐ 101 (11‐1F4) for the treatment of amyloid light chain (“AL”) amyloidosis.

Mannheim/Wetzlar, Germany. Leica Microsystems CMS GmbH has entered into an exclusive, worldwide licensing agreement with Columbia University in New York to commercialize SCAPE microscopy for Life Science applications.

The sophisticated attack on Ukraine’s power grid last year plunged 225,000 people into darkness for days, and put America’s own aging, sprawling system under the spotlight.